Renneville A, Van Galen P, Canver MC, et al. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood. 2015;126(16):1930-1939.
Renneville A, Abdelali RB, Chevret S, et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget. 2014;5(4):916-932. DOI:
Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247-1254.
Aline Renneville, Ph.D.
Aline Renneville is a research scientist I in the Cancer Program of the Broad Institute of MIT and Harvard, where she works under the direction of Benjamin L. Ebert to identify and validate proteins that can be targeted by new molecules from the immunomodulatory drugs family (derivatives of thalidomide) and identify diseases that potentially are susceptible to these new molecules.
Prior to joining the Broad Institute in May 2017, Renneville completed a postdoctoral fellowship at Brigham and Women’s Hospital in Boston. She had previously worked at the Laboratory of Hematology at the Biology and Pathology Center, Lille University Hospital, France.
Renneville obtained her Pharm.D. and Ph.D. from the University of Lille, France.
Contact Aline Renneville via email at email@example.com.